Antibody-Drug Conjugate Hits Recommended Phase 3 Dose in EGFR-Mutated Lung Cancer
An investigational EGFR x HER3 antibody-drug conjugate showed promising efficacy and a manageable safety profile in previously treated EGFR-mutated lung ...
An investigational EGFR x HER3 antibody-drug conjugate showed promising efficacy and a manageable safety profile in previously treated EGFR-mutated lung ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine